CONSULTING AGREEMENT

Effective April 21, 2026 (“Effective Date”), Dr. Eli Wallace (“Consultant”) and BridgeBio Oncology Therapeutics, Inc. (“Company”) agree as follows:

1.

Services; No Violation of Rights or Obligations. Consultant agrees to undertake and complete the Services (as defined in Exhibit A) in accordance with and on the schedule specified in Attachment A. The only consideration due Consultant regarding the subject matter of this Agreement is set forth on Attachment A. Unless otherwise specifically agreed upon by Company in writing (and notwithstanding any other provision of this Agreement), all activity relating to Services will be performed by and only by Consultant or by employees of Consultant and only those such employees who have been approved in writing in advance by Company.Consultant agrees that it will not (and will not permit others to) violate any agreement with or rights of any third party or, except as expressly authorized by Company in writing hereafter, use or disclose at any time Consultant’s own or any third party’s confidential information or intelle

…

IMMUNOME, INC

2024 INDUCEMENT PLAN

EFFECTIVE AS OF: OCTOBER 3, 2024

AMENDED BY THE COMPENSATION COMMITTEE AS OF: MAY 8, 2025 and MAY 12, 2026

1. GENERAL.

(a) Eligible Award Recipients.The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A person who previously served as an Employee or Director will not be eligible to receive Awards under the Plan, other than following a bona fide period of non-employment. Persons eligible to receive grants of Awards under this Plan are referred to in this Plan as “Eligible Employees.” These Awards must be approved by either a majority of the Company’s “Independent Directors” (as such term is defined in Nasdaq Marketplace Rule 5605(a)(2)) (“Independent Directors”) or the Company’s compensation committee, provided such committee is comprised solely of Independent Directors (the “Independent Compensation Committee”) in order to comply with the exempt

…

July 13, 2026

Nitin Dahiya

48 Bedford Road

Summit, NJ 07901

n2dahiya@gmail.com

Re:Offer and Terms of Employment

Dear Nitin,

It gives me great pleasure to offer you the position of Chief Financial Officer for Energy Vault Holdings, Inc. (the “Company”). If you accept this offer, the terms and conditions of this offer letter agreement (the “Agreement”), in addition to the attachments enclosed with this Agreement, will apply to your at-will employment with the Company:

1.Start Date and Duties. If you accept this offer, and contingent on the other conditions set forth herein, your first day of employment will be 27 July, 2026. You will report to Robert A. Piconi, Chairman, Co-Founder & Chief Executive Officer. You shall perform duties consistent with your position in a professional and competent manner, and throughout your employment with the Company devote your time to such matters as the Company may reasonably require. You shall use your best efforts to complete all assignments and adhere to the Company’s procedures and policies in effect.

…

CALISTOGA RESILIENCY CENTER, LLC

4360 Park Terrace Drive, Suite 100
Westlake Village, CA 91361

					New York, New York August 4, 2025
Re:    Amendment No. 1 to the Note Purchase Agreement

…

Exhibit 10.7

ENERGY VAULT HOLDINGS, INC.
2022 EQUITY INCENTIVE PLAN
NOTICE OF STOCK OPTION GRANT

You have been granted the following option to purchase shares of the Common Stock of Energy Vault Holdings, Inc. (the “Company”) on the terms and conditions set out below:

Name of Optionee:    [______]

Total Number of Shares:    [______]

Type of Option (U.S. Tax Status):    [Incentive Stock Option][Nonstatutory Stock Option]

Exercise Price per Share:    [______]

Date of Grant:    [______]

Vesting Commencement Date:    [______]

Vesting Schedule:    [To be specified in the individual award agreements]

Expiration Date:    [______]. This option expires earlier if your Service terminates earlier, as described in the Stock Option Agreement, and may terminate earlier in connection with certain corporate transactions as described in Article 9 of the Plan.

…

THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. LICENSE AND SUPPLY SECOND AMENDMENT This LICENSE AND SUPPLY SECOND AMENDMENT (“Second Amendment”) is entered into as of 20 April 2026 (the “Second Amendment Effective Date”) by and between Aquestive Therapeutics, Inc., a Delaware corporation having its principal place of business at 30 Technology Drive, Warren, New Jersey 07059 (“Aquestive”), and Atnahs Pharma UK Limited, a company registered in England and Wales having its principal place of business at Sovereign House, Miles Gray Road, Basildon, Essex SS14 3FR (“Pharmanovia”). Aquestive and Pharmanovia are sometimes referred to hereinafter individually as a “Party” and collectively as the “Parties.” RECITALS: A. Aquestive and Pharmanovia entered into a License and Supply Agreement related to the Product in certain territories as specified therein on September 26, 2022, which was subsequently amended by a

…

DMS_US.374368937.12 124054739.9 LEASE AGREEMENT BETWEEN 184 PROPERTY OWNER, LLC, a New Jersey limited liability company, LANDLORD, -AND- AQUESTIVE THERAPEUTICS, INC., a Delaware corporation, TENANT DATED: , 2026

---

TABLE OF CONTENTS Page -i- ARTICLE 1 DEFINITIONS ................................................................................................. 4 ARTICLE 2 DEMISE, TERM.............................................................................................. 5 ARTICLE 3 BASIC RENT; ADDITIONAL RENT ............................................................ 6 ARTICLE 4 REAL ESTATE TAXES ................................................................................. 7 ARTICLE 5 OPERATING EXPENSES ............................................................................ 10 ARTICLE 6 ELECTRICITY .............................................................................................. 12 ARTICLE 7 MAINTENANCE; ALTERATIONS; REMOVAL OF TRADE FIXTURES ...................................................................

…

DATED 08 May 2026

(1) ACHIEVE PHARMA UK LIMITED

(2) ACHIEVE LIFE SCIENCES, INC.

(3) RICHARD STEWART

SETTLEMENT AGREEMENT

WITHOUT PREJUDICE AND SUBJECT TO CONTRACT

---

THISAGREEMENTis made on 08 May 2026

BETWEEN:-

(1) ACHIEVE PHARMA UK LIMITED(company number 06751116) whose registered office is at 10 Station Road, Henley-On-Thames, Oxfordshire, RG9 1AY (the "Company");

(2) ACHIEVE LIFE SCIENCES, INC.whose registered office is at 22722 29th Dr. SE Suite 100, Bothell, WA, 98021 (the "Achieve Inc."); and

(3) RICHARD STEWARTof (the "Executive").

WHEREAS:-

(A)

The Executive is employed by the Company as Chairman and Chief Executive Officer of the Company and Chief Executive Officer of Achieve Inc. pursuant to a contract between the Executive and the Company dated 9 May 2025 as amended or varied from time to time (the "Service Agreement").

(B)

…

Achieve Life Sciences, Inc.

Employment Agreement

This Employment Agreement (this “Agreement”) is entered into by and between Andrew D. Goldberg, MD (the “Executive”) and Achieve Life Sciences, Inc., a Delaware corporation (the “Employer” or the “Company”) as of April 16, 2026 (the “Effective Date”). The terms of the Executive’s employment with the Company (“Employment” and commencement thereof, the “Start Date”) are set forth in this Agreement. Defined terms used in this Agreement, and not defined in line, are set forth in Section 7.

1.

Duties and Scope of Employment.

The Employer agrees to employ the Executive in the position of Chief Executive Officer (“CEO”), reporting directly to the Company’s Board of Directors (the “Board”). The Executive shall have such duties, authority and responsibilities that are commensurate with the position of CEO.

…

EXECUTIONVERSION

OMNIBUSAMENDMENTTOLOAN,SECURITYANDCOLLATERAL MANAGEMENT AGREEMENT, dated as of May 4, 2026 (this “Amendment”), amongPhillip Street Middle Market Lending Investments LLC, as the borrower (the “Borrower”), PhillipStreet BDC LLC, as thecollateral manager(the“Collateral Manager”), and Ally Bank, as the arranger (the “Arranger”), as the administrative agent (the “Administrative Agent”) and asthe swingline lender (the “Swingline Lender”).

WHEREAS, the Borrower, the Collateral Manager, the Arranger, the Swingline Lender, the other Lenders from time to time parties thereto, the Administrative Agent, Phillip Street BDC LLC, as the transferor, Phillip Street Middle Market Lending Investment Holdings LLC, as the equityholder and State Street Bank and Trust Company, as the collateral custodian, are party to the Loan, Security and Collateral Management Agreement, dated as of February 10, 2023 (as may be amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”);

…

***Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) of the type that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[…***…]”) in this exhibit.***

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT

THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of July 8, 2026 and made effective as of June 30, 2026 (the “First Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and KYVERNA THERAPEUTICS, INC., a Delaware corporation with offices located at 5980 Horton St., Suite 200, Emeryville, CA 94068 (“Borrower”).

…

April 13, 2026

Nadia Dac
via email to […***….]

Re:Employment Terms

Dear Nadia:

Kyverna Therapeutics, Inc. (the “Company”) is pleased to offer you employment beginning on May 4, 2026 (the “Start Date”); provided, however, if your employment does not commence on the Start Date, this letter shall be null and void and without force or effect.

Position

Your position will be Chief Commercial Officer of the Company with responsibilities, duties, and authority as usual and customary for such position, reporting to the Company’s Chief Executive Officer and Executive Chairperson of the Board of Directors (the “Board”). In this position, you will be permitted to work remotely, subject to reasonable business travel. The Company may change your position, duties, and work location from time to time in its discretion, subject to the severance protections outlined below.

…